News Releases
Metacrine Reports First-Quarter 2022 Results
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its first-quarter 2022 financial results and provided a business update.
May 12, 2022
Metacrine Reports Fourth-Quarter 2021 Results
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its fourth-quarter 2021 financial results.
Mar 30, 2022
Metacrine Announces Executive Leadership Changes
SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today announced that Ms. Trisha Millican has resigned her position as chief financial officer. Ms.
Feb 24, 2022
Metacrine Announces Resignation of Chief Medical Officer
SAN DIEGO, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that Hubert C. Chen, M.D., chief medical officer, has resigned to pursue
Dec 27, 2021
Metacrine Reports Third-Quarter 2021 Results
SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today reported its third-quarter 2021 financial results.
Nov 11, 2021
Displaying 1 - 10 of 65